FOCUS Wealth Advisors LLC Invests $1.61 Million in Johnson & Johnson (NYSE:JNJ)

view original post

FOCUS Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJGet Rating) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 9,068 shares of the company’s stock, valued at approximately $1,610,000. Johnson & Johnson makes up approximately 1.1% of FOCUS Wealth Advisors LLC’s holdings, making the stock its 22nd biggest holding.

Other hedge funds have also made changes to their positions in the company. Family CFO Inc bought a new position in Johnson & Johnson during the fourth quarter worth $26,000. RE Dickinson Investment Advisors LLC lifted its stake in Johnson & Johnson by 163.3% during the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after purchasing an additional 98 shares during the last quarter. Advanced Research Investment Solutions LLC lifted its stake in Johnson & Johnson by 200.0% in the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after buying an additional 120 shares during the last quarter. Professional Financial Advisors LLC lifted its stake in Johnson & Johnson by 47.9% in the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after buying an additional 68 shares during the last quarter. Finally, Joseph P. Lucia & Associates LLC bought a new stake in Johnson & Johnson in the first quarter valued at $38,000. Institutional investors and hedge funds own 68.59% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent research reports. Morgan Stanley cut their target price on Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating on the stock in a research note on Monday, September 12th. Daiwa Capital Markets initiated coverage on Johnson & Johnson in a research note on Wednesday, June 22nd. They issued an “outperform” rating on the stock. UBS Group cut their target price on Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Citigroup cut their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Finally, SVB Leerink cut their price objective on shares of Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $189.78.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $166.28 on Tuesday. The business’s 50-day moving average price is $168.96 and its 200 day moving average price is $174.33. The firm has a market cap of $437.18 billion, a P/E ratio of 24.20, a PEG ratio of 2.99 and a beta of 0.61. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. The firm had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. Johnson & Johnson’s revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.48 earnings per share. As a group, sell-side analysts predict that Johnson & Johnson will post 10.7 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.72%. The ex-dividend date was Monday, August 22nd. Johnson & Johnson’s payout ratio is currently 65.79%.

Johnson & Johnson declared that its Board of Directors has authorized a share buyback program on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 1.2% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s management believes its stock is undervalued.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts